EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	517.50B
Revenue (ttm)	96.04B
Net Income (ttm)	24.87B
Shares Out	36.62M
EPS (ttm)	n/a
PE Ratio	20.81
Forward PE	11.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,241
Average Volume	274,641
Open	13,870
Previous Close	13,820
Day's Range	13,790 - 14,130
52-Week Range	10,000 - 18,800
Beta	0.51
RSI	55.51
Earnings Date	Oct 28, 2025

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for pidemics in South Korea. It offers Euvichol, Euvichol Plus, and Euvichol-S, an oral cholera vaccine developed to prevent cholera; and EuCorVac-19, a subunit vaccine.The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits; and rCRM197, a diphtheria toxoid vaccine. In addition, it offers CMO services comprising of drug product production, cell bank production, drug product production, and drug substance production. Further, t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650